Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cost of Revenue: 2023-2024

Historic Cost of Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Dec 2024 value amounting to $7.8 million.

  • Tonix Pharmaceuticals Holding's Cost of Revenue fell 12.09% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 24.40%. This contributed to the annual value of $7.8 million for FY2024, which is 63.78% up from last year.
  • Tonix Pharmaceuticals Holding's Cost of Revenue amounted to $7.8 million in FY2024, which was up 63.78% from $4.7 million recorded in FY2023.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Cost of Revenue ranged from a high of $7.8 million in FY2024 and a low of $4.7 million during FY2023.
  • Moreover, its 2-year median value for Cost of Revenue was $6.3 million (2023), whereas its average is $6.3 million.
  • Data for Tonix Pharmaceuticals Holding's Cost of Revenue shows a peak YoY spiked of 63.78% (in 2024) over the last 5 years.
  • Over the past 2 years, Tonix Pharmaceuticals Holding's Cost of Revenue (Yearly) stood at $4.7 million in 2023, then skyrocketed by 63.78% to $7.8 million in 2024.